TL;DR
The sinus reducer may improve symptoms in selected patients, but the reported periprocedural complications and limited evidence to date on long-term outcomes should enter into the decision whether to provide this treatment to the individual patient.
Refractory angina affects patients who remain symptomatic despite optimal medical therapy and for whom further revascularization is not feasible. Therapeutic options for this population are limited. The coronary sinus reducer (CSR) has emerged as a device-based treatment aimed at improving symptoms and functional...
Resistant angina despite optimal medical treatment (OMT) is a common condition in patients with chronic coronary syndrome (CCS) that reduces their quality of life. In these patients, the presence of chronic total occlusion (CTO) is a strong predictor of incomplete revascularization. A better understanding of the...
Despite advances in pharmacological and interventional treatments, acute coronary syndromes (ACS) remain a leading cause of death and high morbidity worldwide, particularly among the elderly. Due to age-related physiological changes, a greater burden of atherosclerosis, and a higher prevalence of cardiovascular a...
Background Statins remain the cornerstone of pharmacological prevention for atherosclerotic cardiovascular disease (ASCVD) because of their proven ability to reduce low-density lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE). However, many patients continue to experience ASCVD events desp...
RATIONALE Coronary heart disease (CHD) is the leading cause of death globally. CHD mortality rates remain steady in low- and middle-income countries but are declining in high-income countries, meaning more people are living with CHD and need support to manage their symptoms and prognosis. Exercise-based cardiac rehabil...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
